Company intelligence / Profile preview

Ajax SC

New York City, New York, United Statesajaxsc.ca ↗

Ownership: Private
Development stage: Other

Overview

Ajax Therapeutics is developing highly selective Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms. Their compounds have demonstrated superior selectivity and efficacy in preclinical models, with significant reductions in mutant allele fraction in bone marrow and spleen compared to existing Type I JAK inhibitors. The company leverages computational chemistry and structural biology for drug design, aiming to improve efficacy while reducing off-target effects.

Therapeutic areas: HematologyOncology
Modalities: Small moleculeType II JAK2 inhibitor
Industry: Biotech

Partnerships

Schrödinger, Inc. — strategic partnership for molecular simulation software-driven drug discovery; integrated team collaboration model between Schrödinger scientists and Ajax scientists.

Beyond the preview

Go deeper on Ajax SC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ajax SC.

Explore the full profile